Paper
0
396MO Anti-claudin 18.2 (CLDN18.2) antibody-drug conjugate (ADC) IBI343 in patients (pts) with solid tumors and gastric/gastro-esophageal junction adenocarcinoma (G/GEJ AC): A phase I study
Authors
Journal
Published
Jun 1, 2024
Show more
Save
Tip0
TipSave
Abstract
Paper PDF
This paper's license is marked as closed access or non-commercial and cannot be viewed on ResearchHub. Visit the paper's external site.